F4 Pharma


About F4 Pharma

F4 Pharma GmbH is a development stage bio-pharmaceutical company established 2013 in Vienna. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases.

The company aims to become a leader in the development and commercialisation of pharmaceuticals targeting vascular leak syndrome and inflammation. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as graft rejection after transplantation, septic and hemorrhagic shock, or Dengue shock syndrome (see facts about Dengue >>). In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction.

Therapeutic focus - Inflammatory Response Syndrome (IRS)

F4 Pharma GmbH has identified peptides addressing these pathomechanisms. They potently inhibit acute inflammatory reactions and prevent capillary leak via a novel mechanism of action. The most advanced product of F4 Pharma GmbH – FX06 – prevents reperfusion injury after myocardial infarction as well as organ tranplantation and aims at markets with high medical needs.

[Founders >]


©2017 F4 Pharma GmbH i.G.  •  info@f4-pharma.com  •  Page last modified: 04.07.2017